This document discusses childhood leukemia. It begins by stating that childhood malignancy accounts for 31% of cancers in children under 15 years of age, with an incidence of 4.5 cases per 100,000 children. It then covers topics such as the classification, etiology, pathogenesis, clinical manifestations, diagnosis, and management of the main types of childhood leukemia - ALL, AML, CML, and JMML.
leukemia is one among the common congenital malformations in children. it is also called as cancer of blood cells where immature blood cells are formed due to mutations in progenitor stem cell. This content includes types of leukemia especially categorized in children with description of diagnosis and management.
Definition
A group of malignant diseases in which genetic abnormalities in a hematopoietic cell give rise to an unregulated clonal proliferation of cells
The progeny of these cells have a growth advantage over normal cellular elements, with an increased rate of proliferation & a decreased rate of spontaneous apoptosis
Disruption of normal marrow function, leading to marrow failure
leukemia is one among the common congenital malformations in children. it is also called as cancer of blood cells where immature blood cells are formed due to mutations in progenitor stem cell. This content includes types of leukemia especially categorized in children with description of diagnosis and management.
Definition
A group of malignant diseases in which genetic abnormalities in a hematopoietic cell give rise to an unregulated clonal proliferation of cells
The progeny of these cells have a growth advantage over normal cellular elements, with an increased rate of proliferation & a decreased rate of spontaneous apoptosis
Disruption of normal marrow function, leading to marrow failure
Leukemia, were surviving is regarded as a victory, a disease that still acts as a risk factor among the folks of Hiroshima and Nagasaki, stays as one of the fields to be looked forward for the further research. The above presentation includes the topics to be covered during a presentation on Leukemia. Apt for the students of Pharmacology.
acute leukemia
For More Medicine Free PPT - http://playnever.blogspot.com/
For Health benefits and medicine videos Subscribe youtube channel - https://www.youtube.com/playlist?list=PLKg-H-sMh9G01zEg4YpndngXODW2bq92w
What is Acute Lymphoblastic Leukemia?
Acute Lymphoblastic leukemia (ALL), is a cancer that starts from white blood cells called lymphocytes in the bone marrow (the soft inner part of the bones, where new blood cells are generated).
http://www.bmthospitalindia.com/Adult-Acute-Lymphoblastic-Leukemia.html
Leukemia, were surviving is regarded as a victory, a disease that still acts as a risk factor among the folks of Hiroshima and Nagasaki, stays as one of the fields to be looked forward for the further research. The above presentation includes the topics to be covered during a presentation on Leukemia. Apt for the students of Pharmacology.
acute leukemia
For More Medicine Free PPT - http://playnever.blogspot.com/
For Health benefits and medicine videos Subscribe youtube channel - https://www.youtube.com/playlist?list=PLKg-H-sMh9G01zEg4YpndngXODW2bq92w
What is Acute Lymphoblastic Leukemia?
Acute Lymphoblastic leukemia (ALL), is a cancer that starts from white blood cells called lymphocytes in the bone marrow (the soft inner part of the bones, where new blood cells are generated).
http://www.bmthospitalindia.com/Adult-Acute-Lymphoblastic-Leukemia.html
Transplant in pediatrics in Acute lymphoblastic Luekemia in CR1Dr. Liza Bulsara
to transplant or not to transplant pediatric luekemia in CR1 Has also been a controversial topic . here we give clear recommendation to transplant in difeerent biology group
Newer biomarkers,techniques & their inclusion in 2016 WHO classification for leukaemia/lymphomas increases the responsibility of the pathologists, requiring to develop an integrated multidisciplinary approach for reporting.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
1. m/c childhood malignancy
31 % of all cancer in children <15 Yr of age
Incidence 4.5 cases per 100,000 children
Dr Chandan Barnwal MD
(Pediatrics)
2. Define and classify leukemia
Understand the etio-pathogenesis and it`s
Clinical manifestations
Able to list down the laboratory
investigations required for diagnosis
Understand the basic management of
leukemia
Dr Chandan Barnwal MD
(Pediatrics)
3. Group of malignant disease
in which
genetic abnormalities in a hematopoietic cell
give rise to an
unregulated & clonal proliferations of cells.
Dr Chandan Barnwal MD
(Pediatrics)
6. 1. ALL:- m/c i.e. 77% of all childhood leukemia
:- 2 types:- B-ALL & T-ALL
2. AML:- 11%
3. CML:- 2-3%
4. JMML:-1-2%
Sales
ALL
AML
CML
JMML
Dr Chandan Barnwal MD
(Pediatrics)
7. Etiology remains unclear in majority of cases
Most cases are d/t post conceptional somatic
mutations
Pathogenesis:-
Genetic aberrations (mostly acquired)
Translocation / Inversion
Disrupt genes encoding for factors needed
for
Normal differentiation of Hematopoietic
cell
Dr Chandan Barnwal MD
(Pediatrics)
8. Continue…
e.g.
t(8;21) or and i(6)
Chimeric gene
New protein
Block in differentiation
Proliferation of undifferentiated
blast
BUT
Replication rate is slower than
normal blast
Dr Chandan Barnwal MD
(Pediatrics)
12. 1st disseminated cancer shown to be curable
epidemiology:-
Incidence:- 2400 per year in children <15
years
peak age b/w 2-3 YOL
Male > female
Dr Chandan Barnwal MD
(Pediatrics)
13. 1. FAB classification
2. WHO classification:-
based on immuno-phenotype
now most acceptable classification
Dr Chandan Barnwal MD
(Pediatrics)
14. ALL- L1, ALL-L2, ALL-L3
ALL-L1:-
1. m/c i.e. 80-85%
2. Small cell with scanty cytoplasm
3. Small and inconspicous nucleoi
4. Variable cytoplasmic vacuolation
5. Variable basophilic cytoplasm
Dr Chandan Barnwal MD
(Pediatrics)
15. Continue..
ALL-L2:-
1. Large cell with variable cytoplasm
2. One or more nucleoli
3. Variable basophilic cytoplasm
4. Variable cytoplasmic vacoulation
Dr Chandan Barnwal MD
(Pediatrics)
16. Continue…
ALL-L3:-
1. Large cell with moderately abundant
cytoplasm
2. One or more and often prominent nucleoli
3. Prominent cytoplasmic vacuolation
4. Intense basophilic cytoplasm
Dr Chandan Barnwal MD
(Pediatrics)
17. Precursor B-cell, T-cell, Mature B-cell
Precursor B- cell:-
1. m/c i.e. 80-85 %
2. CD10, CD19, CD20, CD18, CD79a, HLA-DR
are positive
3. CD10 is k/a common ALL antigen
4. if CD10 positive:-favourable prognosis
Dr Chandan Barnwal MD
(Pediatrics)
18. Continue…
T cell ALL:-
1. 15 %
2. CD3, CD7, CD2 or CD5 are positive
3. mainly in older age children
4. a/w mediastinal mass, CNS involvement
Dr Chandan Barnwal MD
(Pediatrics)
19. Continue…
Mature B cell- ALL
1. 1-2%
2. CD19, CD20, CD21 & sIg are positive
3. Correlates with L3 leukemia
4. needs intensified regimens
Dr Chandan Barnwal MD
(Pediatrics)
21. Continue…
As disease progresses
1. Signs & symptoms of B/M failure:-
Pallor
Fatigue
Exercise intolerance
Bruising, Epistaxis
Fever- may be caused by secondary infection
Bone pain but tenderness may not be elicited
Dr Chandan Barnwal MD
(Pediatrics)
22. Continue…
2. Signs of organ infiltration:-
a> Hepato-splenomegaly
b> Lymphadenopathy
c> CNS involvement-
Cranial neuropathies,
Headache,
Seizure,
Papilloedema
Retinal hemorrhage
,
Dr Chandan Barnwal MD
(Pediatrics)
23. d> Respiratory distress:-
d/t anemia or airway compression
by
ant mediastinal mass e.g.
Thymus
Mediastinal LN
Dr Chandan Barnwal MD
(Pediatrics)
24. 11 % of all childhood leukemia
More in adolescence
36 % in 15-19 years old
Incidence of all types of AML are uniform
except
Acute Pro-Myelocytic leukemia is more
common in some regions
Dr Chandan Barnwal MD
(Pediatrics)
25. Cellular classification:-
> 25 % blast cell in B/M
with
Early differentiation states of the
myeloid-monocyte-megakaryocyte series of
blood cells
WHO classification:-
Recent classification system
Consider morphology,
chromosome
abnormalities,
gene mutations
Dr Chandan Barnwal MD
(Pediatrics)
26. WHO classification:-
1. AML with recurrent genetic abnormalities:-
a> Good prognosis:- t(2;21), t(15;17), i(10)
b> Bad prognosis:- t(6;9), d(11q23)
2. AML with myelodysplasia related changes:-
Bad prognosis
3. AML not otherwise specified:-
Dr Chandan Barnwal MD
(Pediatrics)
27. Continue..
4. Therapy related myeloid neoplasm:-
Bad prognosis
5. Myeloid sarcoma:-
Bad prognosis
6. Myeloid proliferations related to Down
syndrome:-
Good prognosis
7. Blastic plasmacytoid dendritic cell
neoplasm:-
Dr Chandan Barnwal MD
(Pediatrics)
28. FAB classification:-
M0:- Undifferentiated AML
M1:- AML with minimal differentiation
M2:- AML with maturation
m/c
t(8;21)
good prognosis
M3:- Acute Promyelocytic Leukemia
t(15;17)
good prognosis
Faggets- bundle of Aeur rod
Dr Chandan Barnwal MD
(Pediatrics)
29. Continue…
M4:- Acute Myelomonocytic Leukemia
2nd m/c
inversion of chromosome 16
good prognosis
M5:- Acute Monoblastic Leukemia
t(9;11)
M6:- Acute Erythroblastic Leukemia
M7:- Acute Megakaryoblastic Leukemia
a/w Down syndrome
Dr Chandan Barnwal MD
(Pediatrics)
30. C/F of AML:-
Signs & symptoms of B/M failure similar to ALL
+
1. Blueberry muffin:-
Bluish-Purplish subcutaneous nodule
specially AML-M4, M5
Dr Chandan Barnwal MD
(Pediatrics)
31. Continue..
2. DIC:-
Specially Acute Promyelocytic leukemia
3. Chloroma:-
Extramedullary manifestations of AML
Diagnosed by Tissue biopsy
k/a Granulocytic sarcoma
Dr Chandan Barnwal MD
(Pediatrics)
32. Continue…
4. Higher incidence of infection
5. Lymphadenopathy & Hepatosplenomegaly is
not common
6. More CNS infiltration:-
mostly in M4 & M5
Dr Chandan Barnwal MD
(Pediatrics)
33. 2-3 % of childhood leukemia
Philadelphia chromosome is charasteristic
C/F:-
Non-specific:-
fever,
fatigue,
weight loss,
Anorexia
spleenomegaly:- pain abdomen
Dr Chandan Barnwal MD
(Pediatrics)
34. Cotinue…
Initial Chronic phase (Blast<10%) of 3-4 years
Followed by Accelerated phase (Blast 10-19%)
Followed by Blast crisis phase (Blast >20%)
C/F of Blast phase = AML,
rapidly involves CNS in Blast phase
Dr Chandan Barnwal MD
(Pediatrics)
35. Continue..
Investigations:-
Leucocytosis with Myeloid cell
at
all stage of differentiation
Mild anemia
Thrombocytosis
Diagnosis confirmed by Philadelphia
chromosome
Dr Chandan Barnwal MD
(Pediatrics)
36. Treatment:-
Imatinib:-
Inhibits BCR-ABL tyrosine kinase
Respone in >70% patient of adult
Safety and efficacy = adults
Dasatinib:-
2nd gen of Imatinib
Better response
Hydroxyurea:-
If life threatening C/F
Make leucocyte count normal
HSCT
Dr Chandan Barnwal MD
(Pediatrics)
37. Formerly k/a Juvenile CML
Philadelphia chromosome is absent
Child <2 years of age
Mutation in RAS oncogene pathway
Risk factors:-
NF-1,
Noonan syndrome
Dr Chandan Barnwal MD
(Pediatrics)
43. 15-20 times increased risk
Risk of ALL & AML = General population BUT
for first 3 years of life- AML > ALL
Prognosis:-
ALL:- inferior to general population
AML:- better than general population
Methotrexate is very effective
Dr Chandan Barnwal MD
(Pediatrics)
44. Transient leukemia
Usually resolve within 1st 3 month of life
10% of newborn with Down syndrome
Features:-
Leucocytosis
Anemia & Thrombocytopenia
Blast cell at PBS
Hepato-Spleenomegaly
Dr Chandan Barnwal MD
(Pediatrics)
45. Continue…
Management:-
Temporary Blood Transfusion
No chemotherapy unless life threatening
events
Close follow up
20-30% develop acute leukemia by 3 years
of life
Dr Chandan Barnwal MD
(Pediatrics)